Rocket Pharmaceuticals Announces Board and Officer Changes
Ticker: RCKTW · Form: 8-K · Filed: Sep 29, 2025 · CIK: 1281895
| Field | Detail |
|---|---|
| Company | Rocket Pharmaceuticals, Inc. (RCKTW) |
| Form Type | 8-K |
| Filed Date | Sep 29, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01, $0 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-of-directors, executive-compensation
TL;DR
Rocket Pharma reshuffled its board and execs, expect strategic shifts.
AI Summary
On September 23, 2025, Rocket Pharmaceuticals, Inc. reported changes in its board of directors and executive officers. The filing indicates the election of new directors and the appointment of certain officers, along with updates to compensatory arrangements for key personnel. Specific details regarding the individuals involved and the exact nature of the compensatory changes were not provided in this excerpt.
Why It Matters
Changes in a company's board and executive team can signal shifts in strategy, governance, or operational focus, potentially impacting future performance and investor confidence.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation structures can introduce uncertainty and signal potential strategic shifts, which may carry inherent risks.
Key Players & Entities
- Rocket Pharmaceuticals, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- September 23, 2025 (date) — Date of earliest event reported
FAQ
What specific changes were made to the board of directors?
The filing indicates the election of directors but does not specify the names of the newly elected individuals or any departing directors in this excerpt.
Who were the newly appointed officers?
The filing mentions the appointment of certain officers but does not provide their names or specific roles in this excerpt.
What are the details of the compensatory arrangements for the officers?
The filing notes updates to compensatory arrangements for certain officers, but the specific details of these arrangements are not included in this excerpt.
When was the earliest event reported in this Form 8-K?
The earliest event reported in this Form 8-K was on September 23, 2025.
What is the principal executive office address for Rocket Pharmaceuticals, Inc.?
The principal executive offices are located at 9 Cedarbrook Drive, Cranbury, NJ 08512.
Filing Stats: 651 words · 3 min read · ~2 pages · Grade level 11.3 · Accepted 2025-09-29 17:19:41
Key Financial Figures
- $0.01 — nge on which registered Common stock, $0.01 par value RCKT The Nasdaq Global Ma
- $0 — f the Company's common stock, par value $0.01, upon vesting ("RSUs" and such grant
Filing Documents
- ef20056168_8k.htm (8-K) — 27KB
- 0001140361-25-036556.txt ( ) — 151KB
- rckt-20250923.xsd (EX-101.SCH) — 4KB
- rckt-20250923_lab.xml (EX-101.LAB) — 21KB
- rckt-20250923_pre.xml (EX-101.PRE) — 16KB
- ef20056168_8k_htm.xml (XML) — 4KB
02
Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers. On September 23, 2025, Dr. Gotham Makker resigned from the Board of Directors (the "Board") of the Company, effectively as of September 24, 2025. Dr. Makker's decision to resign from the Board did not involve any disagreement on any matter relating to the Company's operations, policies or practices. On September 23, 2025, the Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Dr. Peter Fong, who currently serves as President of RTW Investments LP, to the Board, effective September 24, 2025. Upon Dr. Fong's appointment to the Board, the Board granted Dr. Fong (i) 30,000 restricted stock units, which convert one-to-one to shares of the Company's common stock, par value $0.01, upon vesting ("RSUs" and such grant, the "First RSU Grant") and (ii) 23,333 RSUs (the "Second RSU Grant"). The First RSU Grant will vest in equal monthly installments over a three-year period, and the Second RSU Grant will fully vest on the first anniversary of the date of grant, in each case subject to Dr. Fong's continued service on the Board. There are no arrangements or understandings between Dr. Fong and any other person pursuant to which Dr. Fong was appointed as a member of the Board. There are no family relationships between Dr. Fong, on the one hand, and any director, executive officer or any other person nominated or chosen by the Company to become a director or executive officer, on the other. There are no related person transactions (within the meaning of Item 404(a) of Regulation S-K promulgated by the Securities and Exchange Commission) between Dr. Fong, on the one hand, and the Company, on the other.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Rocket Pharmaceuticals, Inc. Date: September 29, 2025 By: /s/ Martin Wilson Martin Wilson General Counsel and Chief Corporate Officer, SVP